135 related articles for article (PubMed ID: 33258714)
1. Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
Tian S; Wang F; Lu S; Chen G
Cancer Invest; 2021 Jan; 39(1):62-72. PubMed ID: 33258714
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
3. Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.
Rubie C; Frick VO; Ghadjar P; Wagner M; Justinger C; Graeber S; Sperling J; Kollmar O; Schilling MK
World J Gastroenterol; 2011 Jul; 17(26):3109-16. PubMed ID: 21912453
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
[TBL] [Abstract][Full Text] [Related]
5. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
Lu W; Fu D; Kong X; Huang Z; Hwang M; Zhu Y; Chen L; Jiang K; Li X; Wu Y; Li J; Yuan Y; Ding K
Cancer Med; 2020 Feb; 9(4):1419-1429. PubMed ID: 31893575
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.
Bedoui S; Dallel M; Barbirou M; Stayoussef M; Mokrani A; Mezlini A; Bouhaouala B; Almawi WY; Yacoubi-Loueslati B
Cancer Gene Ther; 2020 May; 27(5):311-318. PubMed ID: 31138901
[TBL] [Abstract][Full Text] [Related]
7. Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
Yaeger R; Paroder V; Bates DDB; Capanu M; Chou J; Tang L; Chatila W; Schultz N; Hersch J; Kelsen D
Clin Colorectal Cancer; 2020 Dec; 19(4):e151-e156. PubMed ID: 32798155
[TBL] [Abstract][Full Text] [Related]
8. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
[TBL] [Abstract][Full Text] [Related]
9. In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
Malla SB; Fisher DJ; Domingo E; Blake A; Hassanieh S; Redmond KL; Richman SD; Youdell M; Walker SM; Logan GE; Chatzipli A; Amirkhah R; Humphries MP; Craig SG; McDermott U; Seymour MT; Morton DG; Quirke P; West NP; Salto-Tellez M; Kennedy RD; Johnston PG; Tomlinson I; Koelzer VH; Campo L; Kaplan RS; Longley DB; Lawler M; Maughan TS; Brown LC; Dunne PD;
Clin Cancer Res; 2021 Jan; 27(1):288-300. PubMed ID: 33028592
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
11. Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
He J; Cheng J; Guan Q; Yan H; Li Y; Zhao W; Guo Z; Wang X
Cancer Sci; 2020 Jan; 111(1):253-265. PubMed ID: 31785020
[TBL] [Abstract][Full Text] [Related]
12. Exploring microRNA patterns as biomarkers of FOLFOX chemotherapy-induced peripheral neuropathy in patients with colorectal cancer.
Ju Y; Baek DH; Choi GE; Jang A
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167209. PubMed ID: 38701955
[TBL] [Abstract][Full Text] [Related]
13. Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
Ge L; Wang YF; Tian JH; Mao L; Zhang J; Zhang JH; Shen XP; Yang KH
J Clin Pharm Ther; 2016 Aug; 41(4):383-91. PubMed ID: 27338003
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
15. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
16. Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
Strauss LG; Hoffend J; Koczan D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1226-34. PubMed ID: 19280186
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer.
Ozaslan E; Topaloglu US; Inanc M; Gokmen Erdem U; Demir H; Arpaci E; Metin Seker M; Karaagac M; Kiziltepe M; Eker B; Ozkan M
J BUON; 2017; 22(4):863-868. PubMed ID: 29155512
[TBL] [Abstract][Full Text] [Related]
18. Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
Schelhaas S; Wachsmuth L; Hermann S; Rieder N; Heller A; Heinzmann K; Honess DJ; Smith DM; Fricke IB; Just N; Doblas S; Sinkus R; Döring C; Schäfers KP; Griffiths JR; Faber C; Schneider R; Aboagye EO; Jacobs AH
J Nucl Med; 2018 Jul; 59(7):1063-1069. PubMed ID: 29476002
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
